Xerava

RSS

eravacycline

Authorised
This medicine is authorised for use in the European Union.

Overview

Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults. ‘Complicated’ means that the infection is difficult to treat because it has spread to the abdominal space.

Xerava contains the active substance eravacycline.

This EPAR was last updated on 22/06/2023

Authorisation details

Product details
Name
Xerava
Agency product number
EMEA/H/C/004237
Active substance
eravacycline
International non-proprietary name (INN) or common name
eravacycline
Therapeutic area (MeSH)
  • Infection
  • Bacterial Infections
Anatomical therapeutic chemical (ATC) code
J01AA
Publication details
Marketing-authorisation holder
PAION Deutschland GmbH
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
20/09/2018
Contact address

Heussstraße 25
52078 Aachen
Germany

Product information

11/05/2023 Xerava - EMEA/H/C/004237 - IAIN/0024

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating
2 ratings